NUT carcinoma is primarily considered an epigenetically driven cancer in which the BRD4–NUT–p300 axis promotes widespread chromatin hyperacetylation and activates the expression of SOX2, MYC, TP63, and likely other transcription factors to drive NC tumorigenesis and SCC phenotype (7, 8, 9). Here, BRD4 is linked to nut midline carcinoma.